1,000 more positions for young people set to come to One Summer Chicago program this year
Chicago Mayor Brandon Johnson on Tuesday kicked off the One Summer Chicago campaign with an ambitious goal.
"We're prepared to hire 29,000 young people," Mayor Johnson said at Uplift Community High School, 900 W. Wilson Ave., in announcing this year's campaign. "That's 1,000 more positions this year."
The program works with local businesses, nonprofits, and city agencies to identify paid positions for teens and young people ages 14 to 24. The jobs are for at least six weeks over the summer.
Participants say it is a way to test out some possible career options while earning a little extra cash.
Positions are available in communities across the city.
The One Summer Chicago program is a partnership between the Mayor's office, the Chicago Department of Family and Support Services, the Chicago Public Schools, the Chicago Park District, the Chicago Housing Authority, the Chicago Transit Authority, City Colleges of Chicago, and community and corporate partners.
There are three interconnected programs that make up One Summer Chicago.
The Chicago Youth Service Corps employs people ages 16 to 24 year-round through programming focused on both leadership development and civic engagement. Chicagobility employs 14- and 15-year-olds through project-based learning and skill-building. The Summer Youth Chicago Employment Program employs people ages 16 to 24 through job placement or training programs geared toward developing career pathways.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
9 hours ago
- Fox Sports
Unrivaled announces NIL deals with 14 college players, including JuJu Watkins and Flau'Jae Johnson
Associated Press INDIANAPOLIS (AP) — JuJu Watkins, Flau'Jae Johnson and Azzi Fudd are three of 14 top women's college basketball players that Unrivaled is signing to NIL deals, the league announced Saturday. It's the second consecutive year that the 3-on-3 league that was founded by Napheesa Collier and Breanna Stewart has had name, image and likeness deals with college players. In it's inaugural season, Unrivaled had deals with Paige Bueckers and Johnson. Watkins, who plays for Southern California but is sidelined with an ACL injury, has also previously been involved with Unrivaled as an investor in its Series A funding round. Johnson, who is at LSU, and Fudd, at UConn, both were on hand for the announcement, as were Notre Dame's Hannah Hidalgo and UConn's Sarah Strong. Other players signed include TCU's Olivia Miles, UCLA's Kiki Rice and Lauren and Sienna Betts, Texas' Madison Booker, Iowa State's Audi Crooks, LSU's MiLaysia Fulwiley, South Carolina Ta'Niya Latson and Michigan's Syla Swords. The players range from sophomores to seniors. Women's basketball players have been able to take advantage of NIL opportunities over the last few years with Caitlin Clark, Angel Reese, Bueckers and Johnson at the forefront of it. Reese played in Unrivaled in its first season. As part of the initiative, the class will be attending a multi-day event at the league's headquarters in Miami, which will include skill development and content shoots. 'This transformational, first-of-its-kind initiative brings together the best of the best and reflects our deep commitment to elevating the women's game and holistically supporting athletes,' Luke Cooper, President of Basketball Operations at Unrivaled, said in the initiative's announcement. 'Investing in elite women's basketball talent is central to Unrivaled's mission.' Unrivaled completed its inaugural season this past March, and is gearing up for its second this coming January. ___ AP WNBA:
Yahoo
15 hours ago
- Yahoo
One of Trump's MAGA allies found his texts to the Tesla billionaire going unanswered.
Elon Musk changed his phone number after his relationship with Trump and the president's administration blew up, according to House Speaker Mike Johnson. Johnson is the latest Trump ally to open up on the ugly divorce on the New York Post's Pod Force One, after White House Chief of Staff Susie Wiles told host Miranda Devine last week that the president and the tech mogul suffered a 'very troublesome' end to their bromance. Johnson revealed on Wednesday's episode that Musk felt so jilted by the Trump administration that he even changed his phone number, leaving Johnson high and dry.
Yahoo
20 hours ago
- Yahoo
Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Carlsmed has set the target range for its initial public offering, outlining plans to raise up to $103.3 million to support development and commercialization of its spine surgery platform. Carlsmed plans to offer 6.7 million shares of common stock at an expected range of $14 to $16 per share, as well as an underwriters' option to purchase more than 1 million shares. The company, which set the price range Tuesday, sells artificial intelligence-enabled software, custom implants and single-use instruments for spine surgeries. Cross-trial comparisons suggest the custom devices may improve alignment and reduce revisions compared to stock implants. Carlsmed's products compete with stock spine implants sold by companies including Medtronic, Johnson & Johnson and Globus Medical. The company is much smaller than its rivals but growing quickly, with sales increasing by almost 100% in 2024 and on track to rise again this year. Dive Insight: Carlsmed is developing its platform to address the limitations of traditional spine fusion procedures. The company has identified the lack of sufficient pre-operative planning, the fit of stock interbody implants and complicated surgical workflows as problems. Targeting a $13.4 billion addressable market, Carlsmed is working to address these issues to improve patient outcomes and cut healthcare costs. The resulting platform uses diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and design custom interbody implants for each patient. Carlsmed collects real-world, post-operative data to improve the planning process. Researchers have generated evidence of the effectiveness of the platform, including through a registry that is tracking real-world clinical outcomes. An interim analysis of 67 adult spinal deformity patients in the registry found the rate of revision surgery attributable to mechanical complications was 1.5% after a mean follow-up of 14.7 months, according to a federal securities filing. The one-year revision rate in another study of stock implants was 8.7%. Carlsmed reported revenue of $27.2 million last year, up almost 100% compared to 2023, and is on track to grow again in 2025. The company generated sales of around $22.2 million over the first half of 2025. Carlsmed plans to keep growing by adding users and increasing use by existing customers. The number of surgeons who have used the platform increased from 103 as of March 2024 to 199 as of June 2025. Carlsmed's IPO paperwork reveals some of the challenges the company is facing as it scales operations. The company's net loss increased last year, rising to $24.2 million, and its reliance on a limited number of contract manufacturing organizations has hurt margins. Delays in the approval of surgical plans or late changes in surgery dates can cause CMOs to charge expedite fees. The fees drove margins down in the second quarter. Carlsmed expects expedite fees to decrease over time as it tries to improve operational processes and procedural workflows used by surgeons. Carlsmed's filing to list on Nasdaq adds to the uptick in medtech IPO activity seen this year. IPO filings are still well down from the pandemic-era peak but, after years of limited activity, some analysts believe a backlog of companies is waiting for favorable conditions to list. The success or failure of companies such as Carlsmed could inform whether the IPO window opens or closes. Recommended Reading The medtech IPO window is finally open. Or is it? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
